公开(公告)号：US20240261308A1

公开(公告)日：2024-08-08

申请号：US18627861

申请日：2024-04-05

申请人： ARCUTIS BIOTHERAPEUTICS, INC.

发明人： David W. OSBORNE ,  David BERK

IPC分类号： A61K31/683 ,  A61K9/00 ,  A61K9/06 ,  A61K31/045 ,  A61K31/122 ,  A61K31/165 ,  A61K31/19 ,  A61K31/343 ,  A61K31/37 ,  A61K31/436 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/655 ,  A61K31/661 ,  A61K31/662 ,  A61K35/04 ,  A61K38/13 ,  A61K47/06 ,  A61K47/10 ,  A61K47/14 ,  A61P17/00

CPC分类号： A61K31/683 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/045 ,  A61K31/122 ,  A61K31/165 ,  A61K31/19 ,  A61K31/343 ,  A61K31/37 ,  A61K31/436 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/655 ,  A61K31/661 ,  A61K31/662 ,  A61K35/04 ,  A61K38/13 ,  A61K47/06 ,  A61K47/10 ,  A61K47/14 ,  A61P17/00

摘要： The present invention is a method and composition for the treatment of skin conditions where the epidermal barrier has decreased function such as when the patient is suffering from eczema, in particular, Atopic Dermatitis. Epidermal barrier function can be significantly improved and the extraction of epidermal lipids can be reduced by using formulations containing high Krafft temperature surfactants, preferably, anionic surfactants.

公开(公告)号：US11980648B2

公开(公告)日：2024-05-14

申请号：US17338882

申请日：2021-06-04

申请人： MIDDLE TENNESSEE STATE UNIVERSITY

发明人： Stephen Wright ,  Shannon Smith ,  Karen Maynard ,  Elliot Altman

IPC分类号： A61K36/258 ,  A61K31/52 ,  A61K31/522 ,  A61K31/662 ,  A61K31/675 ,  A61K31/704 ,  A61K31/7125 ,  A61P31/22

CPC分类号： A61K36/258 ,  A61K31/52 ,  A61K31/522 ,  A61K31/662 ,  A61K31/675 ,  A61K31/704 ,  A61K31/7125 ,  A61P31/22

摘要： This disclosure describes a composition including the ginsenoside 20(S)-Rg3 (also referred to herein as Rg3) and methods of using such a composition. In some embodiments, the composition may be used to treat or prevent an alpha herpesvirus including, for example, herpes simplex virus (HSV)-1 and HSV-2. In some embodiments, the composition is substantially free of other ginsenosides.

公开(公告)号：US20240082213A1

公开(公告)日：2024-03-14

申请号：US18516541

申请日：2023-11-21

申请人： Nexyon Biotech Co., Ltd.

发明人： Jung Taek Seo ,  Seok Jun Moon ,  Sung-Jin Kim

IPC分类号： A61K31/37 ,  A61K31/404 ,  A61K31/473 ,  A61K31/5377 ,  A61K31/56 ,  A61K31/568 ,  A61K31/5685 ,  A61K31/662 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10

CPC分类号： A61K31/37 ,  A61K31/404 ,  A61K31/473 ,  A61K31/5377 ,  A61K31/56 ,  A61K31/568 ,  A61K31/5685 ,  A61K31/662 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10

摘要： The present disclosure relates to a functional composition for the prevention, amelioration or treatment of obesity or lipid-related metabolic disorders, which comprises a steroid sulfatase inhibitor as an active ingredient.

公开(公告)号：US11701333B2

公开(公告)日：2023-07-18

申请号：US16632194

申请日：2018-07-18

申请人： KENT INNOVATION & ENTERPRISE

发明人： Jennifer Hiscock ,  Daniel Mulvihill ,  Gary Robinson

IPC分类号： A61K31/17 ,  A61P31/04 ,  A01N47/30 ,  A01N47/36 ,  A01N47/44 ,  A01N57/22 ,  A61K31/155 ,  A61K31/428 ,  A61K31/513 ,  A61K31/662 ,  A61K45/06

CPC分类号： A61K31/17 ,  A01N47/30 ,  A01N47/36 ,  A01N47/44 ,  A01N57/22 ,  A61K31/155 ,  A61K31/428 ,  A61K31/513 ,  A61K31/662 ,  A61K45/06 ,  A61P31/04

摘要： The present invention relates to certain compounds of formula (I) wherein—Ar is (Ar1) or (Ar2) and to their uses as antibacterial agents. The invention further relates to methods of treatment of bacterial infection with such compounds, optionally in combination with other antimicrobials and to compositions and pharmaceutical formulations containing such compounds. The invention additionally relates to coatings containing such compounds and to items having such coatings.

公开(公告)号：US20230181459A1

公开(公告)日：2023-06-15

申请号：US17891061

申请日：2022-08-18

申请人： ATTILLAPS HOLDINGS INC.

发明人： Frank Anthony SPALLITTA

IPC分类号： A61K9/00 ,  A61K36/324 ,  A61K31/245 ,  A61K31/662 ,  A61K31/661 ,  A61K31/37

CPC分类号： A61K9/0048 ,  A61K9/0053 ,  A61K9/0014 ,  A61K36/324 ,  A61K31/245 ,  A61K31/662 ,  A61K31/661 ,  A61K31/37 ,  A61K45/06

摘要： Embodiments of the invention involve treating ophthalmology conditions by the topical or oral use of acetylcholinesterase inhibitors. By effectively reducing or eliminating the population of demodex mites in affected areas and areas where demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the ophthalmological afflictions than any previously described method. Embodiments of the invention are useful for treating ocular afflictions caused by demodex-induced inflammatory eye conditions, including meibomian gland dysfunction, conjunctivitis, keratoconjunctivitis, hyperemia, blepharitis and dry eye disease.

公开(公告)号：US20190185546A1

公开(公告)日：2019-06-20

申请号：US16319541

申请日：2017-07-26

申请人： Polichem S.A.

发明人： Roberto Burioni ,  Massimo Clementi

IPC分类号： C07K16/08 ,  A61K31/522 ,  A61K31/662 ,  A61P27/00 ,  A61P31/22

CPC分类号： C07K16/087 ,  A61K31/522 ,  A61K31/662 ,  A61K39/42 ,  A61K45/06 ,  A61K2039/505 ,  A61P27/00 ,  A61P31/22 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

摘要： The present invention relates to a combination comprising HSV-1 and HSV-2 binding monoclonal antibodies or fragments thereof and antiviral agents, the pharmaceutical formulations comprising said combination, optionally together with an excipient pharmaceutically acceptable and its use in the prophylaxis and/or treatment of herpes virus infections, including genital herpes, HSV gingivostomatitis and recurrent herpes labialis, herpes simplex encephalitis (HSE), neonatal HSV, HSV disease in the immunocompromised host and HSV keratitis keratoconjunctivitis.

公开(公告)号：US20180303856A1

公开(公告)日：2018-10-25

申请号：US16025199

申请日：2018-07-02

申请人： Metabasis Therapeutics, Inc.

发明人： K. Raja Reddy ,  Jeff Stebbins ,  Serge H. Boyer ,  Mark D. Erion ,  Scott J. Hecker ,  Nicholas Brian Raffaele ,  Brett C. Bookser ,  Venkat Reddy Mali

IPC分类号： A61K31/675 ,  A61K31/542 ,  A61K31/52 ,  A61K31/688 ,  A61K31/683 ,  A61P3/10 ,  C07F9/40 ,  C07F9/655 ,  C07F9/48 ,  A61P3/04 ,  A61K31/662 ,  A61K31/665 ,  A61K45/06 ,  C07D473/16 ,  C07D473/34 ,  C07D473/40 ,  C07F9/30 ,  C07F9/6574 ,  C07F9/6561 ,  C07F9/653 ,  C07F9/32

CPC分类号： A61K31/675 ,  A61K31/52 ,  A61K31/542 ,  A61K31/662 ,  A61K31/665 ,  A61K31/683 ,  A61K31/688 ,  A61K45/06 ,  A61P3/04 ,  A61P3/10 ,  C07D473/16 ,  C07D473/34 ,  C07D473/40 ,  C07F9/303 ,  C07F9/3229 ,  C07F9/40 ,  C07F9/48 ,  C07F9/65312 ,  C07F9/6552 ,  C07F9/6561 ,  C07F9/65616 ,  C07F9/65742 ,  A61K2300/00

摘要： This invention pertains to the use of fused bicycle heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.

公开(公告)号：US20180297935A1

公开(公告)日：2018-10-18

申请号：US15986059

申请日：2018-05-22

申请人： Quadriga Biosciences, Inc.

发明人： Bernd Jandeleit ,  Wolf-Nicolas Fischer ,  Kerry J. Koller ,  Gordon Ringold

IPC分类号： C07C229/42 ,  A61K31/196 ,  A61K31/197 ,  A61K31/245 ,  A61K31/255 ,  A61K31/27 ,  A61K31/336 ,  A61K31/365 ,  A61K31/42 ,  A61K31/519 ,  A61K31/662 ,  A61K45/06 ,  C07C215/68 ,  C07C229/22 ,  C07C229/34 ,  C07C229/60 ,  C07C233/54 ,  C07C237/04 ,  C07C237/30 ,  C07C239/20 ,  C07C271/14 ,  C07C271/22 ,  C07C271/46 ,  C07C291/04 ,  C07C309/69 ,  C07D303/32 ,  C07D303/36 ,  A61K31/137 ,  C07F9/48

CPC分类号： C07C229/42 ,  A61K31/137 ,  A61K31/196 ,  A61K31/197 ,  A61K31/245 ,  A61K31/255 ,  A61K31/27 ,  A61K31/336 ,  A61K31/365 ,  A61K31/42 ,  A61K31/519 ,  A61K31/662 ,  A61K45/06 ,  C07B2200/07 ,  C07C215/68 ,  C07C229/22 ,  C07C229/34 ,  C07C229/60 ,  C07C233/54 ,  C07C237/04 ,  C07C237/30 ,  C07C239/20 ,  C07C271/14 ,  C07C271/22 ,  C07C271/46 ,  C07C291/04 ,  C07C309/69 ,  C07D303/32 ,  C07D303/36 ,  C07F9/4808

摘要： β-Substituted β-amino acids, β-substituted β-amino acid derivatives, and β-substituted β-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.

公开(公告)号：US20180291050A1

公开(公告)日：2018-10-11

申请号：US16005601

申请日：2018-06-11

申请人： Ligand Pharmaceuticals Inc.

发明人： Lin Zhi

IPC分类号： C07F9/6571 ,  C07F9/6574 ,  A61K45/06 ,  A61K31/663 ,  A61K31/662 ,  A61K31/6615

CPC分类号： C07F9/657181 ,  A61K31/6615 ,  A61K31/662 ,  A61K31/663 ,  A61K45/06 ,  C07F9/657163 ,  C07F9/65746 ,  Y02A50/411 ,  A61K2300/00

摘要： Provided herein are cyclic phosphorus-containing prodrug compounds, their preparation and their uses, such as treating diseases via modulating molecular targets in the liver.

公开(公告)号：US20180264015A1

公开(公告)日：2018-09-20

申请号：US15762644

申请日：2016-09-29

申请人： OSAKA UNIVERSITY

发明人： Nobuyuki TAKAKURA ,  Hisamichi NAITO ,  Kazuhiro TAKARA

IPC分类号： A61K31/662 ,  A61K45/00 ,  A61K35/17 ,  A61P37/04 ,  A61K38/00 ,  A61P35/00 ,  A61K39/395

CPC分类号： A61K31/662 ,  A61K31/683 ,  A61K31/685 ,  A61K35/17 ,  A61K38/005 ,  A61K39/39558 ,  A61K45/00 ,  A61K45/05 ,  A61P35/00 ,  A61P37/04

摘要： A lysophospholipid receptor-activating substance is able to normalize abnormal blood vessels in tumors without affecting normal blood vessels and to thus induce or promote infiltration of leukocytes into the whole or partial region of a tumor. Therefore, such a lysophospholipid receptor-activating substance is useful as a leukocyte infiltration promoter and an antitumor immunostimulant. Moreover, such a lysophospholipid receptor-activating substance can enhance cancer immunotherapy when used in combination with cancer immunotherapy, and is therefore useful as an agent for enhancing cancer immunotherapy.